Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Delayed-Start Study to Evaluate the Efficacy and Safety of Exaluren in Alport Syndrome Patients With Nonsense Mutations in COL4A3/4/5 Genes

NCT07523581 is registered in ClinicalTrials.gov with Eloxx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07523581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07523581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Delayed-Start Study to Evaluate the Efficacy and Safety of Exaluren in Alport Syndrome Patients With Nonsense Mutations in COL4A3/4/5 Genes
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2026
Completion date
December 31, 2027
Enrollment
24 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome, autosomal recessive, alport syndrome, x-linked